Trials & Tribulations Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients March 27, 2026Vol.52 No.12By W. Kimryn Rathmell
Trials & Tribulations In the era of immunotherapy, response rate alone fails to predict true patient benefitRegulators must adapt March 27, 2026Vol.52 No.12By Richard M. Goldberg
Trials & Tribulations Why infection and immunity matter for Florida’s cancer patients February 13, 2026Vol.52 No.06By Eduardo Sotomayor
FreeTrials & Tribulations Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore January 30, 2026Vol.52 No.04By Les Biller
Trials & Tribulations A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers January 16, 2026Vol.52 No.02By Kevin King
Trials & Tribulations How a Montefiore Einstein screening program is changing the history of lung cancer in the Bronx January 09, 2026Vol.52 No.1By Brendon M. Stiles
Trials & Tribulations Smoldering multiple myeloma: Rethinking the waiting game November 14, 2025Vol.51 No.42By C. Ola Landgren
Trials & Tribulations How GLP-1RA drugs are reshaping patient physiology and the future of oncology October 31, 2025Vol.51 No.40By Deborah Phippard
FreeTrials & Tribulations Experts warn that loss of carcinogen surveillance threatens to increase cancer incidence October 24, 2025Vol.51 No.39By David M. DeMarini, Rosalie Elespuru, Miriam C. Poirier and Errol Zeiger
Regulatory NewsTrials & Tribulations Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research October 17, 2025Vol.51 No.38By Edison T. Liu
